RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
RenovoRx, Inc.NASDAQ: RNXT
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$52K, compared with $690K a year earlier. Trailing-twelve-month other income / expenses was $600K. Over 3 fiscal years it compounded at +180.2% a year.
Context
- Other income / expenses amounted to 119.5% of revenue in FY2025, down 4894.5 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$52K or moves back toward the trailing-twelve-month quarterly average of $150K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- -37.8%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | -37.8% |
| FY2024 | 2024-12-31 | 2.16M | +85.2% |
| FY2023 | 2023-12-31 | 1.16M | +1808.2% |
| FY2022 | 2022-12-31 | 61K | +109.3% |
| FY2021 | 2021-12-31 | (653K) | — |
Other Income / Expenses vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 other income / expenses of $600K is the 3rd highest of the 6 companies compared; the peer median is $501.25K.
- Its year-over-year change of -58.5% is the 5th highest of 6, against a peer median of -49.5%.
- Other income / expenses amounts to 40.3% of revenue for RNXT, versus a peer median of 114.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.55M | +221.6% | +66.4% | — | |
| LTM Mar 2026 | $697.88K | -49.5% | +70.7% | — | |
| LTM Mar 2026 | $600K | -58.5% | +180.2% | 40.3% | |
| LTM Mar 2026 | $501.25K | +112.9% | +66.3% | — | |
| LTM Mar 2026 | -$17.55M | -1078.4% | — | — | |
| LTM Dec 2025 | -$30.41M | -55.7% | — | 114.5% | |
| Peer median (excluding RNXT) | $501.25K | -49.5% | +66.4% | 114.5% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 43K | 1.12M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 327K |
| Gross Profit | 0 | 0 | 0 | 43K | 796K |
| Gross Margin | — | — | — | 100.0% | 70.9% |
| Research & Development | 3.04M | 4.3M | 5.67M | 6.03M | 6.27M |
| Selling, General & Admin | 2.63M | 5.65M | 5.73M | 4.99M | 7.04M |
| Operating Expenses | 5.67M | 9.95M | 11.4M | 11.01M | 13.31M |
| Depreciation & Amortization | 9K | 6K | 6K | 0 | 2K |
| EBITDA | (5.48M) | (9.83M) | (10.12M) | (8.81M) | (11.17M) |
| EBITDA Margin | — | — | — | -20497.7% | -994.3% |
| Operating Income | (5.67M) | (9.95M) | (11.4M) | (10.97M) | (12.51M) |
| Operating Margin | — | — | — | -25511.6% | -1114.0% |
| Interest Income | 70K | 57K | 0 | 384K | 427K |
| Interest Expense | 904K | 57K | 108K | 0 | 0 |
| Other Income / Expenses | (653K) | 61K | 1.16M | 2.16M | 1.34M |
| Income Before Tax | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Pre-Tax Margin | — | — | — | -20497.7% | -994.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Net Margin | — | — | — | -20497.7% | -994.5% |
| EPS (Basic) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| EPS (Diluted) | (0.40) | (0.54) | (0.50) | (0.37) | (0.32) |
| Weighted Avg Shares | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
| Weighted Avg Shares (Diluted) | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.